Dexamethasone in outcome of patients with hepatitis B virus-related acute-on-chronic liver failure

• Published in: Journal of gastroenterology and hepatology Vol. 29; no. 4; pp. 800 - 806
• Main Authors: Chen, Jun-Feng, Wang, Ke-Wei, Zhang, Shao-Quan, Lei, Zi-Ying, Xie, Jun-Qiang, Zhu, Jian-Yun, Weng, Wei-Zhen, Gao, Zhi-Liang, Lin, Bing-Liang
• Format: Journal Article
• Language: English
• Published: Australia Blackwell Publishing Ltd 01.04.2014
• Subjects: acute liver failure; acute-on-chronic; Adult; Age Factors; Brain Diseases; clinical; dexamethasone; Dexamethasone - administration & dosage; Dexamethasone - therapeutic use; End Stage Liver Disease - drug therapy; End Stage Liver Disease - etiology; End Stage Liver Disease - mortality; End Stage Liver Disease - physiopathology; Female; Follow-Up Studies; Glucocorticoids - administration & dosage; Glucocorticoids - therapeutic use; hepatitis B; Hepatitis B - complications; Humans; Liver Failure, Acute - drug therapy; Liver Failure, Acute - etiology; Liver Failure, Acute - mortality; Liver Failure, Acute - physiopathology; Liver Function Tests; Male; Middle Aged; outcome; Risk Factors; Severity of Illness Index; Survival Rate; Time Factors; Treatment Outcome; dexamethasone; clinical; acute-on-chronic; acute liver failure; hepatitis B; outcome

Background and Aim Acute‐on‐chronic liver failure (ACLF) caused by hepatitis B virus (HBV) is a severe disease with high mortality. Immune injury plays an important role during the early stage of the disease. Our research aimed to investigate the safety and efficacy of dexamethasone therapy for pati...